首页|期刊导航|中国免疫学杂志|布拉氏酵母菌对幽门螺杆菌感染患者肠道菌群和炎症因子水平的影响

布拉氏酵母菌对幽门螺杆菌感染患者肠道菌群和炎症因子水平的影响OA

Effect of Saccharomyces boulardii on gut microbiota and inflammatory factors levels in patients infected with Helicobacter pylori

中文摘要英文摘要

目的:探究幽门螺杆菌(Hp)感染患者使用布拉氏酵母菌散后对肠道菌群及炎症因子的影响.方法:选取2024年11月至2025年6月邢台医学院第二附属医院收治的280例Hp阳性患者作为研究对象,使用随机数字表法将患者按1∶1∶1∶1比例分为A组、B组、C组、D组,70例/组,A组为单纯四联疗法组;B组在四联疗法基础上加用布拉氏酵母菌散,疗程1周;C组采用B组相同剂量布拉氏酵母菌散,但延长疗程至2周;D组将布拉氏酵母菌散剂量减半,疗程2周.采用F检验或χ2检验对四组患者的基本资料、肠道菌群、炎症因子、Hp根除率及不良反应进行分析.对比四组患者治疗前、治疗后1周、2周、3周的肠道菌群、炎症因子水平、肠道屏障功能指标水平.结果:四组患者的基本资料比较结果显示,四组患者在白蛋白(ALB)、性别、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、体重指数(BMI)、碱性磷酸酶(ALP)方面差异有统计学意义(P<0.05).比较四组患者的肠道菌群、炎症因子及肠道屏障功能指标结果显示,四组患者治疗后3周双歧杆菌、乳酸杆菌均依次高于治疗后2周、1周与治疗前,肠杆菌、肠球菌、TNF-α、IL-6、C反应蛋白(CRP)、二胺氧化酶(DAO)、D-乳酸(D-LA)及血清连蛋白(Zonulin)水平治疗后3周均依次低于治疗后2周、1周与治疗前;治疗后1周、2周、3周C组的双歧杆菌、乳酸杆菌均高于A、B、D组,C组的肠杆菌、肠球菌均低于A、B、D组.比较四组患者的Hp根除率及不良反应结果发现,C组的Hp根除率均高于A、B、D组(P<0.05);C组的不良反应发生率均低于A、B、D组,但差异无统计学意义(P>0.05).结论:布拉氏酵母菌散对改善Hp感染患者肠道菌群和炎症因子水平具有良好的治疗效果,并且可有效提高Hp根除率,其中以2次/d、药量0.5 g、疗程2周方案的治疗效果较为显著.

Objective:To investigate the effect of Saccharomyces boulardii powder on intestinal flora and inflammatory factors in patients with Helicobacter pylori(Hp)infection.Methods:A total of 280 Hp-positive patients admitted to the Second Affiliated Hospital of Xingtai Medical College from November 2024 to June 2025 were enrolled as the research subjects.Using the random number table method,the patients were divided into four groups(A,B,C,and D)at a 1∶1∶1∶1 ratio,with 70 patients in each group.Group A received quadruple therapy alone;Group B received quadruple therapy plus Saccharomyces boulardii powder for 1 week;Group C received the same dosage of Saccharomyces boulardii powder as Group B but extended the course to 2 weeks;Group D received half the dosage of Saccharomyces boulardii powder for 2 weeks.F-test or χ² test were used to analyze the baseline data,intestinal flora,inflam-matory factors,Hp eradication rate,and adverse reactions among the four groups of patients.Levels of intestinal flora,inflammatory factors,and intestinal barrier function indicators in the four groups were compared before treatment,as well as at 1 week,2 weeks,and 3 weeks after treatment.Results:Comparison results of the baseline data among the four groups of patients indicated that there were statistically significant differences(P<0.05)in albumin(ALB),gender,alanine aminotransferase(ALT),aspartate aminotrans-ferase(AST),body mass index(BMI),and alkaline phosphatase(ALP)across the four groups;results of comparing the intestinal flora,inflammatory factors,and intestinal barrier function indices of the four groups showed that,in all four groups,levels of Bifido-bacterium and Lactobacillus at 3 weeks after treatment were sequentially higher than those at 2 weeks after treatment,1 week after treatment,and before treatment,while levels of Enterobacter,Enterococcus,TNF-α,IL-6,C-reactive protein(CRP),diamine oxidase(DAO),D-lactic acid(D-LA)and serum Zonulin at 3 weeks after treatment were sequentially lower than those at 2 weeks after treat-ment,1 week after treatment,and before treatment,and that at 1 week,2 weeks,and 3 weeks after treatment,levels of Bifidobacterium and Lactobacillus in Group C were all higher than those in Group A,B and D,while levels of Enterobacter and Enterococcus in Group C were all lower than those in Group A,B and D.Results of comparing Hp eradication rates and adverse reactions among the four groups revealed that the Hp eradication rate in Group C was higher than that in Group A,B and D,with a statistically significant differ-ence(P<0.05),and the incidence of adverse reactions in Group C was lower than that in Groups A,B and D,though the difference was not statistically significant(P>0.05).Conclusion:Saccharomyces boulardii has a good therapeutic effect on improving the intestinal flora and inflammatory factor levels in patients with Hp infection,and can effectively improve the Hp eradication rate.Among them,the treatment regimen of 0.5 g twice a day for 2 weeks has a more significant therapeutic effect.

刘玉龄;窦龙涛;李会龙;张新飞;刘石柱;贾书晓

邢台医学院第二附属医院(邢台市肿瘤医院)消化内科,邢台 054000邢台医学院第二附属医院(邢台市肿瘤医院)普外二科,邢台 054000邢台医学院第二附属医院(邢台市肿瘤医院)消化内科,邢台 054000邢台医学院第二附属医院(邢台市肿瘤医院)消化内科,邢台 054000邢台医学院第二附属医院(邢台市肿瘤医院)消化内科,邢台 054000邢台医学院第二附属医院(邢台市肿瘤医院)医务科,邢台 054000

医药卫生

布拉氏酵母菌散幽门螺杆菌肠道菌群炎症因子

Saccharomyces boulardii powderHelicobacter pyloriGut microbiotaInflammatory factors

《中国免疫学杂志》 2026 (3)

567-573,580,8

邢台市重点研发计划项目社会发展领域专项(2024ZC263).

10.3969/j.issn.1000-484X.2026.03.009

评论